Screening for Anemia in Children with Down Syndrome

Mittal S., LaRosa A., Pereira-Smith S., Boan A. Medical University of South Carolina, Charleston SC

BACKGROUND

- As part of the 2011 AAP health supervision guidelines for children with Down Syndrome (DS), annual screening for iron deficiency anemia (IDA) is recommended between the ages of 1-18 years.
- IDA is associated with cognitive impairment, and children with DS are a particularly vulnerable population for neurocognitive deficits.
- The prevalence of anemia in DS is not well studied and the evidence supporting annual screening is sparse.

OBJECTIVE

- To assess the prevalence of anemia in patients with DS between the ages 1-18 years to provide additional evidence for annual hemoglobin and ferritin screening in patients with DS.

STUDY DESIGN

- Retrospective cohort study from 2012-2016. Data were obtained from electronic medical records (EMR) for all patients with a dx of DS seen in the Medical University of South Carolina’s healthcare system between the ages of 1-18 from 2012-2016.
- Data regarding red blood indices, comorbid diagnoses, medications, and demographic information was collected. Patients were excluded if had a hematologic condition, such as leukemia.
- Data were analyzed by fischer exact test and chi square.

RESULTS & DISCUSSION

Prevalence of Anemia in DS 0-20

<table>
<thead>
<tr>
<th>Source</th>
<th>Rate of Anemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previous DS syndrome study (0-20)</td>
<td>8.1%</td>
</tr>
<tr>
<td>Our study (1-20)</td>
<td>22.5%</td>
</tr>
</tbody>
</table>

Prevalence of Anemia by Age

<table>
<thead>
<tr>
<th>Age of Patient</th>
<th>Percentage with Anemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 to &lt; 5</td>
<td>18.7%</td>
</tr>
<tr>
<td>5 to &lt; 12</td>
<td>33%</td>
</tr>
<tr>
<td>12 to 18 Males</td>
<td>26.1%</td>
</tr>
<tr>
<td>12 to 18 Females</td>
<td>30%</td>
</tr>
<tr>
<td>Total</td>
<td>22.5%</td>
</tr>
</tbody>
</table>

Was Anemia Documented in the Medical Record?

Type of Anemia

- Microcytic
- Normocytic
- Macrocytic

- A total of 200 patients were identified. 22.5% of patients were found to have anemia, which is significantly greater than 8.1% previously reported in a study of 149 children 0-20 with DS.
- The general population of children aged 1-4 had rates of 3.2%, while our population had a rate of 18.7%.
- Adolescent males and females had a surprisingly high rate of anemia - 26% and 30% respectively.
- Down syndrome patients had a high rate of macrocytic anemia (27%).
- The diagnosis of anemia was only documented in 22% (10/45) electronic medical records.

CONCLUSIONS

- The prevalence of anemia in this cohort of children with DS to be significantly higher than the general population.
- Adolescent males and females experience similar rates of anemia as younger children, supporting AAP guidelines for annual screening until the age of 18 years.
- A large number of patients had macrocytic anemia. Macrocytosis in DS can mask the low MCV typically seen in iron deficiency anemia.
- Obtaining a ferritin level can be a useful diagnostic tool for iron deficiency anemia in children with DS.
- Untreated anemia is associated with neurocognitive impairment, and it is concerning that the diagnosis of anemia was often missed by physicians in an already high risk population.
- This results of this study have led to changes in clinical practice and improved screening for anemia in the Down Syndrome Clinic at MUSC.

This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number T73MC22233, Leadership Education in Neurodevelopmental and Related Disorders Training Program. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government.